AstraZeneca Pharma India: Appointment of Chief Financial Officer
AstraZeneca Pharma India (ASTRAZEN) filed a disclosure titled "Appointment of Chief Financial Officer". The company is valued at about ₹15,863 crore.
What happened
AstraZeneca Pharma India (ASTRAZEN) filed a disclosure with the exchanges on 5 November 2026 at 06:00 PM titled "Appointment of Chief Financial Officer".
Company snapshot
AstraZeneca Pharma India is a small-cap company, with a market value of about ₹15,863 crore.
The stock last traded at ₹6,345, against a 52-week range of ₹5,640–₹9,580 (33.8% below the high).
Before this filing the shares had moved +5.2% over the month and −22.7% over three months. Average daily turnover over the last 20 sessions was about ₹5.78 crore.
Promoters held 75.00% at the end of Q1 FY27. Foreign institutions owned 2.68% and domestic institutions 6.08%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 526 | 55.8 | 22.33 |
| Q2 FY26 | 559 | 54.2 | 21.69 |
| Q3 FY26 | 612 | 32.6 | 13.04 |
| Q4 FY26 | 579 | 44.9 | 17.95 |
| Q1 FY27 | 683 | 37.9 | 15.17 |
What history shows
This is not the company's first management change disclosure: BCEIE has 8 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 0.4% on average the next trading day and was up 0.7% on average after five days (8 filings with price data).
Market-wide, 4,282 management change filings with an impact score of 50 or more saw an average next-day move of −0.1%, with 44% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 15 Sept 2026 | Resignation of Director/KMP/SMP | −0.4% | +0.2% |
| 22 Jul 2026 | Resignation of Director/KMP/SMP | −2.7% | +1.2% |
| 21 Jul 2026 | Management change | −0.3% | +0.2% |
| 6 Jul 2026 | Disclosure Under Regulation 30 Of SEBI (Listing Obligations And… | −1.2% | −0.5% |
| 16 Jun 2026 | Disclosure Under Regulation 30 Of SEBI (Listing Obligations And… | +1.1% | +1.1% |
What to watch
- The appointment of a successor and any change in strategy or guidance.
- 5 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Delhi High Court stays NPPA recovery of ₹151 crore for AstraZeneca Pharma
- Delhi High Court Stays NPPA's ₹151-Crore Recovery from AstraZeneca Pharma: Dispute over Price Control of Symbicort Inhaler
- AstraZeneca Pharma Share Price Rises 5.11%: Price Analysis
- AstraZeneca Pharma India NPPA Overcharging Case Delhi High Court
- AstraZeneca Pharma India secures respite in Rs. 151,19,66,035 overcharging case
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.